about
Antibody-targeted radiation cancer therapyTargeted killing of virally infected cells by radiolabeled antibodies to viral proteinsChemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applicationsSynthesis and comparative biological evaluation of bifunctional ligands for radiotherapy applications of (90)Y and (177)Lu.Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection.Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy.Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases.Synthesis and evaluation of a new bifunctional NETA chelate for molecular targeted radiotherapy using(90)Y or(177)Lu.Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models.Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapyNovel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI.Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates.New insights into the mechanisms of action of radioimmunotherapy in lymphoma.Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin.Radioimmunotherapy of solid tumors: searching for the right target.The role of nuclear medicine in modern therapy of cancer.Radioimmunotherapy in mantle cell lymphoma.Escort aptamers: a delivery service for diagnosis and therapy.Effectiveness of combined (131)I-chTNT and radiofrequency ablation therapy in treating advanced hepatocellular carcinoma.
P2860
Q28264580-8E2F8E1B-B671-4EA1-A662-423D3D34D38EQ28469068-7D142A4B-E668-493B-A74D-C4E939B59C76Q33396676-EA676369-8638-4B21-A31F-B537B9DD61F5Q34160678-C183E088-0609-4B73-8E5C-FD3A853EDB81Q35098222-E72B7A51-F4CE-47C7-AEE4-5F7665A64FB7Q35224087-5BF59012-E65E-465C-9DBC-70124842CC1EQ35780034-DC6E6A31-A311-41EC-8493-9DA0387A350FQ35978710-206546D4-2E17-4DA3-920D-7ED857207114Q36247600-2AA75216-70E2-4305-9478-711DAEF6317EQ36316942-4D28CBF2-2675-4225-8329-12EC043DB0ECQ36348748-38839554-AC87-44C1-9034-284645689FBCQ36492441-0C39A86A-CD6B-4EF2-9EC1-1FEC5FBD224FQ36676810-9D168609-F8EC-42CC-8A68-A1965B08F09BQ36813571-569048CC-CC74-49EC-BE70-F2C000DBD746Q37089782-B8066C2E-D332-48AD-A1D9-0E50B741D326Q37222783-D1A8E171-2763-42F7-BB53-5FC462E407A6Q37571360-B0DE6AE5-89E2-4364-AA3C-95EA47F507A4Q37804904-6BA7B334-163B-4AD5-9055-B4668569DDFAQ37996849-8DD82167-A85D-4FA9-A0A1-C384C0120004Q38017790-73C444B2-CAF6-4BAD-8ACA-5C8E10AC5880Q40432036-689BB6AB-9F74-4FD3-A887-07586853480BQ50458927-326ACB3C-EDCD-40B8-93FC-65A41A2E03D5
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Clinical radioimmunotherapy.
@ast
Clinical radioimmunotherapy.
@en
type
label
Clinical radioimmunotherapy.
@ast
Clinical radioimmunotherapy.
@en
prefLabel
Clinical radioimmunotherapy.
@ast
Clinical radioimmunotherapy.
@en
P1476
Clinical radioimmunotherapy.
@en
P2093
P356
10.1016/S1053-4296(00)80045-4
P577
2000-04-01T00:00:00Z